Abstract
Objective: To report the fetal outcome of a baby with paternal exposure to irbesartan and other antihypertensive and antidiabetic drugs. Case: The baby was conceived by in vitro fertilization with an egg obtained from a woman with untreated diabetes and hypertension and the sperm from a male with type-2 diabetes and hypertension. At the time of sperm donation, he was taking irbesartan 150 mg d-1 in addition to amlodipine, aspirin, carvedilol, glibenclamide, hydrochlorothiazide, metformin, ramipril, and triazolam. At 38 weeks gestation, a 3,090 g female baby was delivered by cesarean section due to placenta previa. At 40 months postnatal age, the baby was 18 kg with normal growth and development. Conclusion: This case suggests that paternal exposure to irbesartan as part of a combination therapy with other antihypertensive drugs and antidiabetics, does not alter sperm cells or increase the risk for fetal malformations.
| Original language | English |
|---|---|
| Pages (from-to) | 24-26 |
| Number of pages | 3 |
| Journal | Journal of Clinical Pharmacology and Pharmacoepidemiology |
| Volume | 1 |
| Issue number | 1 |
| Publication status | Published - 2010 |
Keywords
- Angiotensin II type 1 receptor blockers
- Antihypertensive agents
- Paternal exposure
- Sartans
ASJC Scopus subject areas
- Pharmacology (medical)
- Epidemiology
- Pharmacology
UN SDGs
This output contributes to the following Sustainable Development Goal(s)
